Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
36 hedge funds and large institutions have $18.6M invested in Lumos Pharma, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 11 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 36 → 36 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
20% less capital invested
Capital invested by funds: $23.3M → $18.6M (-$4.71M)
55% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$172K |
| 2 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$100K |
| 3 |
KFI
Key Financial Inc
West Chester,
Pennsylvania
|
+$87.3K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$25.7K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.43K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$818K |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$253K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$107K |
| 4 |
PAG
Paladin Advisory Group
Clive,
Iowa
|
-$35.1K |
| 5 |
BlackRock
New York
|
-$15.7K |
LUMO Hedge Fund Activity: Q2 2022 in Review
36 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q2 2022, worth a combined $18.6M — down 20% from $23.3M a quarter earlier.
Fund positioning in LUMO was balanced in Q2 2022: 4 funds opened new positions, 4 closed out, 5 added to existing stakes and 11 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $172K. The largest seller was NEA Management Company, cutting an estimated $818K.
- 36 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $18.6M of Lumos Pharma, Inc. Common Stock stock for Q2 2022, down 20% quarter-over-quarter.
- 4 funds opened new Lumos Pharma, Inc. Common Stock positions in Q2 2022 and 4 closed out, a net change of 0 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q2 2022 was Opaleye Management, an estimated $172K added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q2 2022 was NEA Management Company, an estimated $818K sold.
Based on aggregated 13F filings for Q2 2022.